title: Effect of fragmented Lactobacillus amylovorus CP1563 on lipid metabolism in overweight and mildly obese individuals: a randomized controlled trial.
abstract: BACKGROUND
  Previously, we showed that fragmented Lactobacillus amylovorus CP1563 (CP1563) functions as a dual agonist of peroxisome proliferator-activated receptor α and γ in vitro and in vivo.
  
  
  OBJECTIVE
  Here, we examined the safety and effect of CP1563 ingestion on body fat in obese class I participants in a double-blinded, placebo-controlled, randomized clinical trial (RCT).
  
  
  METHODS
  In the RCT, 200 participants with a body mass index (BMI) of 25-30 kg/m(2) consumed test beverages with or without 200 mg of CP1563 daily for 12 weeks. In total, 197 subjects completed the study without any adverse effects.
  
  
  RESULTS
  Body fat percentage, whole body fat, and visceral fat were significantly decreased in the test group compared with the placebo group (p<0.001, p<0.001, and p<0.001, respectively). Triglycerides, total cholesterol, LDL-cholesterol, and diastolic blood pressure showed significant reductions in the test group compared with the placebo group (p<0.001, p<0.001, p<0.001, and p<0.001, respectively). Additionally, significant differences in the changes in blood glucose, insulin, homeostasis model assessment-insulin resistance (HOMA-IR), and uric acid were observed between the two groups (p<0.001, p=0.004, p<0.001, and p<0.001, respectively). Improvements in anthropometric measurements and markers were observed in obese class I subjects in the test group.
  
  
  CONCLUSIONS
  Daily consumption of beverages containing fragmented CP1563 for 12 weeks by obese class I subjects improved anthropometric measurements and markers related to lipid and glucose metabolism without any adverse effects. These results suggest that the consumption of foods containing fragmented CP1563 reduces body fat and prevents metabolic syndrome.
authors.affiliation: Research & Development Center, Asahi Group Holdings, Ltd., Chuo-ku, Sagamihara-shi, Kanagawa, Japan.
authors.forename: Futoshi
authors.initials: F
authors.lastname: Nakamura
authors.affiliation: Research & Development Center, Asahi Group Holdings, Ltd., Chuo-ku, Sagamihara-shi, Kanagawa, Japan.
authors.forename: Yu
authors.initials: Y
authors.lastname: Ishida
authors.affiliation: Research & Development Center, Asahi Group Holdings, Ltd., Chuo-ku, Sagamihara-shi, Kanagawa, Japan.
authors.forename: Kohtaro
authors.initials: K
authors.lastname: Aihara
authors.affiliation: Research & Development Center, Asahi Group Holdings, Ltd., Chuo-ku, Sagamihara-shi, Kanagawa, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Sawada
authors.affiliation: Research & Development Center, Asahi Group Holdings, Ltd., Chuo-ku, Sagamihara-shi, Kanagawa, Japan.
authors.forename: Nobuhisa
authors.initials: N
authors.lastname: Ashida
authors.affiliation: Research & Development Center, Asahi Group Holdings, Ltd., Chuo-ku, Sagamihara-shi, Kanagawa, Japan.
authors.forename: Tomonori
authors.initials: T
authors.lastname: Sugawara
authors.affiliation: Research & Development Center, Asahi Group Holdings, Ltd., Chuo-ku, Sagamihara-shi, Kanagawa, Japan.
authors.forename: Yumeko
authors.initials: Y
authors.lastname: Aoki
authors.affiliation: I-Food Service Division, Clinical Support Corporation, Chuo-ku, Sapporo, Hokkaido, Japan.
authors.forename: Isao
authors.initials: I
authors.lastname: Takehara
authors.affiliation: Medical Corporation Hokubukai Utsukushigaoka Hospital, Kiyota-ku, Sapporo, Hokkaido, Japan.
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Takano
authors.affiliation: Research & Development Center, Asahi Group Holdings, Ltd., Chuo-ku, Sagamihara-shi, Kanagawa, Japan; shigeru.fujiwara@asahigroup-holdings.com.
authors.forename: Shigeru
authors.initials: S
authors.lastname: Fujiwara
keywords: PPARα/γ dual agonist; biogenics; fragmented lactic acid bacteria; paraprobiotics; visceral fat